Parkinson’s disease with camptocormia
Citations
17 citations
Cites background from "Parkinson’s disease with camptocorm..."
...Approximately 20% of PD patients with camptocormia might receive some benefit from levodopa (Bloch et al. 2006)....
[...]
17 citations
17 citations
Cites background from "Parkinson’s disease with camptocorm..."
...However, we regarded these as confounding factors because quantities of TABLE 2 Postural abnormality and related factors in PD Author Year N Postural Abnormality Method Related Factors Djaldetti et al.20 1999 8 Camptocormia Unmeasured Male sex, duration of PD, H & Y stage Bloch et al.21 2006 63 Camptocormia Unmeasured UPDRS Part III scores Tipple et al.1 2009 275 Camptocormia Unmeasured (partially goniometer) Age, duration of PD, dosage of L-dopa, duration of L-dopa treatment, H & Y stage, rigidity and bradykinesia item score of UPDRS PPart III, dementia, vertebral surgery Seki et al.13 2011 531 Camptocormia Measured (photograph) Age, H & Y stage, UPDRS Part III scores, total LED, dosage of L-dopa, urinary incontinence, severe constipation Kashihara et al.22 2012 365 Dropped head Unmeasured H & Y stage Camptocormia H & Y stage, age, female sex, deterioration of MMSE score, duration of PD, lumber pain Lateral flexion H & Y stage, age, female sex, deterioration of MMSE score, duration of PD, lumber pain Song et al.14 2013 705 Camptocormia Measured (goniometer) Duration of PD, H & Y stage, UPDRS Part III scores, motor fluctuation, dyskinesia, MMSE Oeda et al.7 2013 216 Dropped head Measured (photograph) H & Y stage, history of postural abnormalities induced by dopamine agonists Camptocormia Age, duration of PD, H & Y stage, UPDRS Part III score, dosage of L-dopa, LED of dopamine agonists, vertebral disease, mental symptoms Zinazzi et al.2 2015 1,631 Lateral flexion Measured (goniometer) Age, body mass index, duration of PD, H & Y stage, UPDRS scores, LED, ongoing pharmacological therapy, falls, veering gait Khlebtovsky et al.19 2017 190 Camptocormia Measured (spinal mouse) Age, older age at disease onset, duration pf PD, UPDRS motor and posture scores, back pain Ameghino et al.16 2018 63 Dropped head Unmeasured Urinary incontinence, exposure to pribedil and quetiapine Camptocormia Age, history of orthopedic disorder, duration of PD, H & Y stage, UPDRS Part III scores, exposure to dopamine agonists and amantadine Lateral flexion H & Y stage, less depression, exposure to amantadine Present study 2018 1,117 Dropped head Measured (photograph) Age, male sex, H & Y stage during ON time Camptocormia Duration of PD, H & Y stage during ON and OFF times, spinal disease, LFA to the right Lateral flexion Anterior flexion angle MOVEMENT DISORDERS CLINICAL PRACTICE 2019; 6(3): 213–221. doi: 10.1002/mdc3....
[...]
...1999 8 Camptocormia Unmeasured Male sex, duration of PD, H & Y stage Bloch et al.(21) 2006 63 Camptocormia Unmeasured UPDRS Part III scores Tipple et al....
[...]
...Bloch et al.(21) found that the UPDRS Part III scores of patients with waist bending were significantly high, especially on the walk item....
[...]
...Bloch et al.21 found that the UPDRS Part III scores of patients with waist bending were significantly high, especially on the walk item....
[...]
17 citations
Cites background from "Parkinson’s disease with camptocorm..."
...First, postural control is often impaired for the altered muscular tonus of axial muscles, unresponsive to L-DOPA medication....
[...]
...In general, camptocormia does not respond well to treatment with L-DOPA [11, 12]....
[...]
...In a case–control study on PD patients with camptocormia and age-matched patients also suffering from PD but not exhibiting the sagittal deformity [12], the authors concluded that PD with camptocormia shows specific characteristics such 1 3 as axial rigidity, disorders and instability during gait, limited response to L-DOPA also for the axial symptoms, which cannot be observed in the control group and may be due to a significantly higher neurological dysfunction, although other authors hypothesized that it might simply reflect a more severe parkinsonian phenotype or a longer duration of the symptoms [1]....
[...]
...Scoliosis in PD patients usually shows a single curve, is more common in female patients rather than in males and is not respondent to L-DOPA treatment [22, 30]....
[...]
...In addition to age and sex and the severity of the PD symptoms, other clinically relevant variables usually taken into account in scientific papers are the duration of the symptoms, i.e., the time period between the diagnosis of PD and the collection of the data, the possible presence of back pain which is assessed by means of its conventional grading systems and the possible treatment with L-DOPA and/or deep brain stimulation....
[...]
16 citations
References
76,181 citations
70,887 citations
35,518 citations
19,347 citations
11,606 citations